A stock image of medical professionals.Photo:Getty
Getty
On Thursday, a group of researchers from the University of British Columbia in Canada published a study in the scientific journalStem Cell Reportsthat found that lab mice that received bone marrow transplants from other mice that had a protein associated with Alzheimer’s experienced rapid cognitive decline.
“This supports the idea that Alzheimer’s is a systemic disease where amyloids that are expressed outside of the brain contribute to central nervous system pathology,” Wilfred Jefferies, an immunologist and an author on the study, toldNeuroscience News.
“As we continue to explore this mechanism, Alzheimer’s disease may be the tip of the iceberg and we need to have far better controls and screening of the donors used in blood, organ and tissue transplants as well as in the transfers of human-derived stem cells or blood products," Jefferies added.In the study, the researchers used both healthy mice and mice showing signs of Alzheimer’s disease, and transplanted bone marrow to them from mice with a hereditary form of Alzheimer’s. The healthy mice began developing signs of Alzheimer’s at 9 months old, and the mice that already had the Alzheimer’s protein began to experience cognitive decline at 6 months old.
“The fact that we could see significant behavioral differences and cognitive decline in the APP-knockouts at 6 months was surprising but also intriguing because it just showed the appearance of the disease that was being accelerated after being transferred,” the study’s first author, Chaahat Singh, told Neuroscience News.
Never miss a story — sign up forPEOPLE’s free daily newsletterto stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
The University of British Columbia researchers wrote that bone marrow and other medical donors should be screened for Alzheimer’s before they are able to give a transfusion.
However, several other scientists who spoke withMedscapewarned that the risk of a human receiving Alzheimer’s via a bone marrow or stem cell transfer is very low.
Paul Morgan, a dementia researcher at Cardiff University in the United Kingdom, told the scientific outlet that the study involved a “very specific experimental situation,” and that it is a “gargantuan leap” to say that there is a significant risk in humans for spreading Alzheimer’s through transplants.
source: people.com
